NO DECISIONDismissed97% confidenceGPT-5.4 (OpenAI)
Question
Will the results be positive?
Found
Reviewed
Summary
No public efficacy readout for NCT05987332 was available as of April 12, 2026. Sponsor updates said topline results were delayed from late March and then scheduled for disclosure on April 13, 2026, so there is not yet trial-specific evidence to label the readout positive or negative.
Sources
Sponsorir.ideayabio.com
IDEAYA Biosciences Upcoming Investor Relations Events and Updated Darovasertib Topline Results Guidance from Phase 2/3 OptimUM-02 Trial
Sponsor said OptimUM-02 topline data would not arrive in late March and updated guidance to mid-April 2026, indicating the readout was still pending.
View source
Sponsorir.ideayabio.com
IDEAYA Biosciences to Announce Topline Results from Phase 2/3 OptimUM-02 Trial in Metastatic Uveal Melanoma on Monday, April 13, 2026
Sponsor announced it would disclose topline OptimUM-02 results on Monday, April 13, 2026 at 8:00 a.m. ET, so as of April 12 no positive/negative public readout had occurred.
View source